> Addressing questions about the direction of its R&D efforts, Merck said it would not follow rival Pfizer out the door of the heart-disease laboratory. Report
> India's Glenmark Pharmaceuticals said it has started distribution of a morphine-based solution in the US market through its subsidiary here. Report
> Warner Chilcott posted third quarter net income of $40.1 million or $0.16 per share, compared to $5.8 million or $0.02 per share in the prior year quarter. Report
> Czech-based generics drug maker Zentiva reported a percent rise in third-quarter net profit on better sales and confirmed its full-year guidance and dividend policy. Report
> India's Aurobindo Pharma saw its stock soar after it announced the FDA's approval for its generic version of Pfizer's Zoloft oral concentrate. Report
> Novavax reported a net loss of $7.8 million ($0.12 per share) for the third quarter of 2008, compared with a loss of $9.0 million ($0.15 per share) for the third quarter of 2007; its net cash burn for the quarter was $8.3 million. Release
> Targeted Genetics announced today that H. Stewart Parker, president and CEO, and Barrie J. Carter, executive vice president and chief scientific officer have resigned effective November 6, 2008. Release
> Duska Therapeutics and DSM Pharmaceuticals have entered into a preliminary agreement to collaborate on the manufacture of commercial batches of ATPace for Duska's planned pivotal Phase 3 clinical trial for paroxysmal supraventricular tachycardia. Release
> Elder Pharmaceuticals entered into an agreement with Daiwa Pharmaceuticals of Japan for manufacturing and marketing some of the Japanese company's products in India. Report
> Boston Scientific won the FDA nod to market its Apex PTCA Dilatation Catheter. Release
> Cubist Pharmaceuticals has been named by the Boston Globe as one of the top places to work in Massachusetts. Release
> As part of its mission to advance science education, the Amgen Foundation, in partnership with three of Europe's leading
universities, today announced the launch of the Amgen Scholars Program in Europe. Release
> With generic Wellbutrin XL competitors eating away at its profits, Canada's Biovail announced that the company could incur up to $100 million in restructuring charges over the next several quarters as the company shifts its focus to other opportunities. Report
> Genentech and OSI Pharmaceuticals announced that a global phase III study of Tarceva--dubbed Saturn--met the primary endpoint of progression-free survival. Report
> In another pipeline-building move, California's Onyx Pharmaceuticals has shelled out $320 million for BTG's preclinical anticancer compound, BGC 945. Report
And Finally... Very young children who sustain a head injury--a possible sign of excessive risk-taking--may be more likely to be diagnosed with attention-deficit hyperactivity disorder later, researchers report. Report